United States Blood Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states blood glucose monitoring market size is expected to increase from USD 14.67 billion in 2025 to USD 16.84 billion in 2026 and reach USD 30.83 billion by 2031, growing at a CAGR of 12.86% over 2026-2031. This report is Segmented by Device Type (SMBG Devices: Glucometers, Test Strips, Lancets; CGM Devices: Sensors, Durables), Patient Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), and End-User (Hospitals & Clinics, Homecare Settings, Diagnostic Centers). The Market Forecasts are Provided in Terms of Value (USD).

United States Blood Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence

CDC reported that 38.4 million Americans, or 11.6% of the population, lived with diabetes in 2025, while prevalence among adults 65+ climbed to 29.2%. The burden is disproportionately heavy in Alabama, Mississippi, and Louisiana, where obesity exceeds 35% and endocrinology resources are sparse, spurring telehealth-enabled CGM demand. Direct medical costs totaled USD 307 billion in 2024; however, CGM uptake among Type 2 basal insulin users remained below 8%, highlighting untapped expansion opportunities. Prediabetes affects 97.6 million adults and carries a 70% risk of progressing to Type 2 within a decade, feeding a pipeline that sustains device volumes. Employer plans now reimburse CGM for prediabetic staff to avert downstream expenses, broadening the user base. Consequently, continuous monitoring is shifting from episodic testing toward universal surveillance across risk cohorts.

Technological Advances in CGM

Four sensor platforms received FDA clearance between March and September 2024, including Dexcom’s OTC Stelo, Abbott’s Lingo, Medtronic’s Simplera, and Senseonics’ 365-day Eversense. One-year implantability reduces adhesive dermatitis, which previously caused 18% of discontinuations within six months. Abbott’s partnership with Medtronic to embed Libre sensors into MiniMed pumps underscores the strategic importance of interoperability, enabling patients to assemble personalized hybrid solutions. Dexcom priced Stelo at USD 99 for a two-sensor month, demonstrating that retail shelves can reach the 30 million prediabetic Americans lacking prescription coverage. As wear duration stretches from 14 days to 365 days, per-day costs decrease toward USD 1, unlocking Medicaid and cash-pay segments that have been long tethered to USD 0.15 test strips.

High Cost of CGM Devices

Out-of-pocket CGM costs range from USD 1,200 to USD 2,400 annually, compared to USD 180 to USD 360 for SMBG, a six-fold premium that dissuades uninsured and high-deductible plan members. Survey work revealed that 34% of Type 2 users abandoned CGM within 90 days due to cost concerns, reverting to bulk-purchased strips at USD 0.15 each. Rebates negotiated by pharmacy benefit managers seldom reach the checkout counter, preserving the sticker shock of USD 300-400 per month. Dexcom’s USD 99 Stelo cuts the list price but shifts the full cost to consumers, limiting its reach. Rural counties with fewer than 50,000 residents post CGM adoption rates 62% below urban peers, magnifying health inequity.

Other drivers and restraints analyzed in the detailed report include:

• Medicare Reimbursement Expansion
• Interoperable “DIY Looping” Ecosystems
• Semiconductor Sensor Supply Risk

Segment Analysis

Self-monitoring systems captured 56.71% of the United States blood glucose monitoring market share in 2025, driven by three-year hospital contracts that bundled meters and strips at USD 0.80-1.20 per test. Test strips dominate revenue because basal insulin users typically burn through 730-1,095 strips annually, and proprietary chemistries help keep customers loyal. Lancets face commoditization, with generic units at USD 0.02 eroding branded margins. Conversely, CGM sensors are slated to post a 13.69% CAGR through 2031, fueled by 365-day implantables and OTC channels. Sensors account for about 72% of CGM revenue due to their steady replacement cadence, while transmitters are subsidized to secure subscription economics.

Glucometers persist in critical-care wards because the CGM mean absolute relative difference of 9-12% is outside the ±5% insulin-dosing tolerance FDA set in 2024. The reuse of strips and lancets still undercuts sensor economics in low-income homes, despite infection control warnings. The transition from 14-day to 365-day sensors reduces the daily cost and mitigates adhesive-related dropout, which is observed in 18% of patients within six months. Dexcom’s Stelo exploits prediabetes retail channels, while safety-engineered hospital lancets maintain a 40% premium due to OSHA mandates.

Complete Report Scope:

• By Device Type
  • SMBG Devices
    • Glucometers
    • Test Strips
    • Lancets
  • CGM Devices
    • Sensors
    • Durables
• By Patient Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
• By End-user
  • Hospitals & Clinics
  • Homecare Settings
  • Diagnostic Centers

List of Companies Covered in this Report:

• Abbott Laboratories
• Acon Laboratories
• AgaMatrix
• Arkray
• Ascensia
• Bionime
• Dexcom
• Lifescan
• Medtronic
• Roche
• Rossmax

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support